$GSAC

GELSTAT CORP

Pharmaceutical preparations · Pink Limited

0.000 +33.33% as of 10/28/2026, 6:58:38 PM · delayed

Sentiment

BULLISH BEARISH

No open positions yet.

No threads yet for $GSAC. Be the first to post.

Official links

Filings

1-Z Mon May 11 2026 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov
1-U Thu Apr 30 2026 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov
1-SA Mon Sep 29 2025 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov View
1-K Tue Apr 29 2025 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov View
1-SA Thu Sep 26 2024 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov View
1-K Tue May 07 2024 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov View
1-U Tue Nov 28 2023 00:00:00 GMT-0500 (Eastern Standard Time) SEC.gov
1-SA Thu Oct 12 2023 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov View

All filings

Timeline

import 9/20/2026 GSAC added from Pink Limited universe
filing 5/10/2026 1-Z filed
filing 4/29/2026 1-U filed
filing 9/28/2025 1-SA filed
filing 4/28/2025 1-K filed
filing 9/25/2024 1-SA filed
filing 5/6/2024 1-K filed
filing 11/27/2023 1-U filed
filing 10/11/2023 1-SA filed
filing 5/9/2023 1-K filed

Company reliability

–

No resolved statements yet.

Revenue

No SEC revenue data.

CEO compensation

$100K (FY 2007)

Kieft (current CEO) - $300K total disclosed since 2004

Kieft

10-K

Provisional - extracted from filings, not verified.

FY 2005 $100K extracted
FY 2004 $100K extracted

Notes & debt

Provisional - extracted from filings, not verified.

IN DEFAULT · $210K in arrears
$0 matured Feb 26, 2024 1-SA · 2025-09-29

Quote

In connection with the issuance of the convertible note, the Company issued a common stock purchase warrant to the same investor to purchase up to 10,000,000 shares of common stock.
$210K matured Dec 31, 2025 1-SA · 2025-09-29

Quote

On January 1, 2024, the note was modified to a two-years convertible note in the amount of $210,371, convertible into Company Stock at $0.0004 per share and a warrant with a five-year term, exercisable into 131,481,963 common shares and an exercise price of $0.0004 per share.
$0 matured Jul 22, 2026 1-SA · 2025-09-29

Quote

The maturity date of the convertible note is July 22, 2026.
NEARING / AGED
$41K — 0% 1-SA · 2025-09-29

Quote

On June 14, 2023, the Company issued a two-year $41,158 convertible note to a vendor as a result of a settlement agreement for warehouse space.
$191K — 0% 1-SA · 2025-09-29

Quote

Convertible notes On February 23, 2022, the Company issued a $120,000 convertible note at a discounted price of $100,000.
$24K — 1-SA · 2025-09-29

Quote

On July 22, 2022, the Company issued 2,000,000 common stock purchase warrants in connection with the issuance of a convertible note in the amount of $24,000.
OTHER ISSUANCES
$165K — 0% 1-SA · 2025-09-29

Quote

As described in Note 4, the Company issued a two-year $165,000 convertible note which carries an original issue discount (OID) of 10%.
$30K — 1% 1-SA · 2025-09-29

Quote

On July 1, 2025, our Chairman agreed to invest the principal into a longer-term instrument and the Company entered into a revised convertible note on July 1, 2025 which included the additional $30,000 loan.
$210K — 1% 1-SA · 2025-09-29

Quote

In addition, our Chairman invested an additional $32,500 and agreed to restructure the revolving credit line into a new, 24 months convertible note for a total amount of $210,371.
$240K — 1-SA · 2025-09-29

Quote

NOTE 9 – Subsequent Events In September 2025, the Company amended two convertible notes with principal amount of $240,000 and $41,158, to extend the maturities by two years, with no changes to existing terms and no additional OID.
$26K — 1-SA · 2025-09-29

Quote

During 2024 the Company raised $26,000 through the execution of convertible notes and received additional funds from related parties totaling $27,500 and it intends to use the issuance of convertible notes in the foreseeable future to provide liquidity to support expanded operations.
$26K — 1-SA · 2025-09-29

Quote

Management intends to raise money through the issuance of certain debt instruments, including Convertible Notes as well as planning a new Regulation A Funding to be filed in late 2025 or early 2026.
$0 — 1-SA · 2025-09-29

Quote

In June 2025, an extension to the convertible note was agreed to with the seller. (see Note XX, “Subsequent Events”) New Contracts Prior to conclusion of the asset purchase agreement from Duos, GelStat, on behalf of the newly formed engineering subsidiary, GSAC Engineering, secured an annual support and services recurring revenue contract with a regional government entity in the state of Florida covering multiple facilities.
$41K — 1-SA · 2025-09-29

Quote

The landlord accepted a convertible note in the amount of $41,158 as full and final settlement of all past rent and early termination penalties.
$165K — 1-SA · 2025-09-29

Quote

During 2023, we raised working capital through the issuance of two convertible notes in the amount of $165,000 for the purchase of certain assets from a third party company and an additional $120,000 from a shareholder along with the restructuring of a previous convertible note from that shareholder for a period of 24 months.
$165K — 1-SA · 2025-09-29

Quote

During 2022, management was engaged in reviewing potential opportunities in the security management market, specifically for jail management and also a “waste to energy” technology that would encompass licensing and operating a proprietary technology currently available in Europe. (See “ Recent Developments ” below.) Our primary source of working capital has been funds raised in the Regulation A+ offering, convertible notes and a revolving credit line provided by the Company’s Chairman.
No notes match this filter.

Top predictors

No resolved predictions on $GSAC yet.

Upcoming resolutions

Nothing awaiting resolution.